Introduction This computational modeling study introduces a novel Explainable Artificial Intelligence (XAI) framework for optimizing single-dose psilocybin treatment protocols through personalized intervention modeling using publicly available mental health datasets. All results presented are derived from novel simulated data and predictive modeling only, no...
ABSTRACT Three novel 14 C-labelled isotopologues of the psychoactive agents psilocin, psilocybin and 5-methoxy- N, N -dimethyltryptamine (5-MeO-DMT) were synthesised, all labelled at the 2-position of the indole. The syntheses involved incorporating the 3-dimethylaminoethyl substituent common to all three substances onto a 4- or 5-substituted indole intermed...
Mental health disorders and associated economic impact continue to rise domestically and globally. In 2023, to expand treatment options for individuals suffering Treatment Resistant Depression (TRD), the Therapeutic Goods Administration (TGA) of Australia has permitted psychiatrist lead psilocybin-assisted psychotherapy. Psilocybin, a psychedelic tryptamine ...
Psilocybin analogues have been synthesized comprising a non-hydrolysable P-C bond to evaluate the biological activity and the selectivity towards 5-HT2A R, 5-HT2B R and the TNAP receptor.
The psychedelic compound psilocybin has shown therapeutic benefit in the treatment of numerous psychiatric diseases. A recent randomized clinical trial conducted at Johns Hopkins Bayview Medical Center demonstrated the efficacy of psilocybin-assisted therapy in the treatment of Major Depressive Disorder (MDD). Similarly, a phase IIb study evaluating psilocyb...
Psilocybin (a serotonin 2A, or 5-HT2A, receptor agonist) has shown preliminary efficacy as a treatment for mood and substance use disorders. The current report utilized positron emission tomography (PET) with the selective 5-HT2A receptor inverse agonist radioligand [11C]MDL100,907 (a.k.a. M100,907) and cortical regions of interest (ROIs) derived from restin...
BackgroundGrowing evidence suggests psilocybin, a naturally occurring psychedelic, is a safe and promising pharmacotherapy for treatment of mood and substance use disorders when administered as part of a structured intervention. In most trials to date, psilocybin dose has been administered on a weight-adjusted basis rather than the more convenient procedure ...
Psilocybin is a hallucinogenic compound found in fungi and is currently evaluated inclinical trials for treatment of depression, anxiety and addiction. Psilocybin is aprodrug of the pharmacologically active metabolite, psilocin. The synthetic route topsilocybin relies on synthesizing psilocin from the starting material, 4-hydroxyindoleand latter converting p...
ObjectivesClassic psychedelics (serotonin 2A receptor agonists) and dissociative hallucinogens (NMDA receptor antagonists), though differing in pharmacology, may share neuropsychological effects. These drugs, however, have undergone limited direct comparison. This report presents data from a double-blind, placebo-controlled within-subjects study comparing th...
RationaleAlthough psilocybin and dextromethorphan (DXM) are hallucinogens, they have different receptor mechanisms of action and have not been directly compared.ObjectiveThis study compared subjective, behavioral, and physiological effects of psilocybin and dextromethorphan under conditions that minimized expectancy effects.MethodsSingle, acute oral doses of...
Acute and enduring adverse effects of psilocybin have been reported anecdotally, but have not been well characterized. For this study, 1993 individuals (mean age 30 yrs; 78% male) completed an online survey about their single most psychologically difficult or challenging experience (worst "bad trip") after consuming psilocybin mushrooms. Thirty-nine percent ...
UnlabelledThe definition New psychoactive substances (NPS) refers to emerging drugs whose chemical structures are similar to other psychoactive compounds but not identical, representing a "legal" alternative to internationally controlled drugs. There are many categories of NPS, such as synthetic cannabinoids, synthetic cathinones, phenylethylamines, piperazi...
Despite suggestive early findings on the therapeutic use of hallucinogens in the treatment of substance use disorders, rigorous follow-up has not been conducted. To determine the safety and feasibility of psilocybin as an adjunct to tobacco smoking cessation treatment we conducted an open-label pilot study administering moderate (20 mg/70 kg) and high (30 mg...
The Panaeolus bisporus(Malen con & Bertault) Ew.Gerhardt is a toadstool species in the world,as poisonous as it contains small quantities of the psilocybin group of hallucinogens,mycelium is white with obvious clamp-connection,which belongs to Basidiomycota,Agaricales,Bolbitiaceae.The suitable and optimal carbon sources,nitrogen sources,carbon nitrogen ratio...
